| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | Bosutinib | FIMM | pan-cancer | AAC | -0.078 | 0.8 |